merck
Biotech

Merck pays $9.2B for owner of flu antiviral J&J rejected

Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & Johnson last year.
James Waldron Nov 14, 2025 8:25am
Whitewater kayaking

Charles River lays off 70 staffers as strategic shift begins

Nov 14, 2025 4:40pm
a lot of scissors

Sensei shrinks workforce by 65% as layoff warning comes to pass

Nov 14, 2025 10:33am
Chutes Ladders Canada British columbia

Ovid eyes next chapter with CEO transition—Chutes & Ladders

Nov 14, 2025 8:30am
Cartoon of businessmen standing around a broken target

BMS-J&J blood thinner fails phase 3, denting blockbuster hopes

Nov 14, 2025 8:10am
workers

Fierce Biotech Layoff Tracker 2025: Kite, Ventus & more

Nov 14, 2025 7:00am
More News

Analysts skeptical Applied can bring rare disease drug to market

Nov 14, 2025 5:25am

European VC Medicxi closes €500M biotech fund

Nov 14, 2025 3:00am

AbbVie to end Calico collab, lay off scientists: Stat

Nov 13, 2025 3:59pm

Pfizer finalizes Metsera buy after contentious Novo bidding war

Nov 13, 2025 12:43pm